Gioacchino Angarano

Gioacchino Angarano

Auto-generated profile, based on publicly available information

Gioacchino Angarano

Clinic of Infectious Diseases, University of Bari, Bari, Italy

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in AIDS
Verified
Journal Article
Closed access
AMAntonella D'ARminio Monforte
Antonella D'ARminio Monforte
ALAlessandro Cozzi Lepri
Alessandro Cozzi Lepri
GRGiovanni Rezza
Giovanni Rezza
PPPatrizio Pezzotti
Patrizio Pezzotti
AAAndrea Antinori
Andrea Antinori
MMMauro Moroni
Mauro Moroni
To evaluate the frequency of discontinuation of the first highly active antiretroviral regimen (HAART) and the factors predictive of discontinuing for toxicity and failure in a population-based cohort of HIV-positive individuals in Italy, naïve from antiretrovirals at enrolment. The study population consisted of individuals who initiated HAART and had at least one follow-up visit. The primary end-points were discontinuation of any component of HAART for drug toxicity and discontinuation for failure. Survival analyses were performed to identify predictive factors for reaching the two end-points. Eight hundred and sixty-two individuals initiated HAART; in 727 of them (84.3%) this consisted of two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (PI). Over a median follow-up of 45 weeks, 312 patients (36.2%) discontinued therapy: 182 (21.1%) discontinued due to toxicity, 44 (5.1%) due to failure. The probability of discontinuing HAART at 1 year was 25.5% [95% confidence interval (CI), 21.9–28.9] due to toxicity and 7.6% (95% CI, 4.9–10.3) due to failure. Independent factors associated with discontinuation for toxicity were: gender [relative hazard (RH) = 0.51; 95% CI, 0.32–0.80 for men versus women], type of treatment (indinavir-containing regimens, RH = 1.94; 95% CI, 1.10–3.41 and ritonavir-containing regimens, RH = 3.83; 95% CI, 2.09–7.03 versus hard-gell saquinavir) and time spent on treatment (RH = 0.89; 95% CI, 0.80–0.98 for each additional month). Discontinuation due to failure was independently associated with the most recent HIV-RNA (RH = 3.20; 95% CI, 1.74–5.88 for log10 copies/ml higher), and with type of treatment (indinavir-containing regimens, RH = 0.21; 95% CI, 0.06–0.78 and ritonavir-containing regimens, RH = 0.23; 95% CI, 0.04–1.26 versus hard-gell saquinavir). If the current HAART regimen caused no toxicity, less than 10% of naïve patients discontinue their first HAART regimen because of failure after 1 year from starting therapy.

15 September 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AWAnnemarie M. J. Wensing
Annemarie M. J. Wensing
DVDavid A. van de Vijver
David A. van de Vijver
GAGioacchino Angarano
Gioacchino Angarano
BÅBirgitta Åsjö
Birgitta Åsjö
CBClaudia Balotta
Claudia Balotta
SPSpread Programme
Spread Programme
BackgroundInfection with drug-resistant human immunodeficiency virus type 1 (HIV-1) can impair the response to combination therapy. Widespread transm

1 November 2000 in AIDS
Verified
Journal Article
Closed access
PMPaolo Maggi
Paolo Maggi
GSGabriella Serio
Gabriella Serio
GEGiuseppe Epifani
Giuseppe Epifani
GFGiuseppe Fiorentino
Giuseppe Fiorentino
ASAnnalisa Saracino
Annalisa Saracino
GPGiuseppe Pastore
Giuseppe Pastore
To evaluate the presence of premature atherosclerotic lesions of epiaortic vessels in HIV-1-infected protease inhibitor-(PI) treated patients compared with PI-naive patients and healthy individuals. One-hundred and two HIV-1-positive patients, including 55 treated with PI for at least 12 months and 47 either naive or treated with PI-sparing regimens, were subjected to epiaortic vessel ultrasonography. These data were compared with those obtained from 104 healthy individuals. Intima characteristics, pulsation and resistance indexes, and minimal, peak and mean speed were evaluated using a colour power doppler. Atherosclerotic plaques were described. Independent risk factors and values for glycaemia, cholesterolaemia and triglyceridaemia were considered. Statistical analysis included the chi-square test, Mantel–Haenszel test, odds ratio and logistic regression analysis. Of the PI-treated patients, 29 out of 55 (52.7%) presented acquired lesions of the vascular wall at ultrasonography, whereas similar lesions were found in seven out of 47 (14.9%) PI-naive patients. Of the 104 healthy individuals, seven cases (6.7%) of intimal medial thickness were noted. A slightly significant correlation was found between carotid lesions and age, male sex and hypercholesterolaemia, whereas cigarette smoking, hypertriglyceridaemia and Centers for Disease Control and Prevention stage significantly increased the risk of vascular lesions (P = 0.022, P = 0.017 and P = 0.079 respectively). However, the highest significance regarded use of PI (P = 0.011). These results were confirmed by logistic regression analysis. These data demonstrate a higher than expected prevalence of premature carotid lesions in the PI-treated compared with PI-naive patients. If confirmed, a periodic ultrasonographic study of the vascular wall should be included in the follow-up of HIV infected patients.

1 June 1998 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
DTDonato Torre
Donato Torre
SCSalvatore Casari
Salvatore Casari
FSFilippo Speranza
Filippo Speranza
ADAlessandra Donisi
Alessandra Donisi
GGGiampietro Gregis
Giampietro Gregis
T†the Italian Collaborative Study Group †
the Italian Collaborative Study Group †
The aim of the present pilot study was to compare the efficacy and safety of trimethoprim (TMP) and sulfamethoxazole (SMX) with those of the standard therapy pyrimethamine (P)-sulfadiazine (S) for the treatment of toxoplasmic encephalitis in patients with AIDS. This was a pilot, multicenter, randomized, and prospective study. Patients were randomly assigned to receive TMP (10 mg/kg of body weight/day) and SMX (50 mg/kg/day) or P (50 mg daily) and S (60 mg/kg/day) as acute therapy (for 4 weeks) and then as maintenance therapy for 3 months at half of the original dosage. Seventy-seven patients were enrolled and randomized to the study: 40 patients were treated with TMP-SMX and 37 were treated with P-S. There was no statistically significant difference in clinical efficacy during acute therapy. In contrast, patients randomized to TMP-SMX appeared more likely to achieve a complete radiologic response after acute therapy. Adverse reactions were significantly more frequent in patients treated with P-S, and skin rash was the most common adverse event noted in these patients. In conclusion, the results of the study suggest that TMP-SMX appears to be a valuable alternative to P-S, in particular in patients with opportunistic bacterial infections.

20 May 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
TPThe Spread Programme
The Spread Programme
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
OPOliver Pybus
Oliver Pybus
GMGkikas Magiorkinis
Gkikas Magiorkinis
AHAngelos Hatzakis
Angelos Hatzakis
AVAnne-Mieke Vandamme
Anne-Mieke Vandamme
The prevalence and the origin of HIV-1 subtype B, the most prevalent circulating clade among the long-term residents in Europe, have been studied extensively. However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced. In the current study we inferred the migration history of HIV-1 subtype B by way of a phylogeography of viral sequences sampled from 16 European countries and Israel. Migration events were inferred from viral phylogenies by character reconstruction using parsimony. With regard to the spatial dispersal of the HIV subtype B sequences across viral phylogenies, in most of the countries in Europe the epidemic was introduced by multiple sources and subsequently spread within local networks. Poland provides an exception where most of the infections were the result of a single point introduction. According to the significant migratory pathways, we show that there are considerable differences across Europe. Specifically, Greece, Portugal, Serbia and Spain, provide sources shedding HIV-1; Austria, Belgium and Luxembourg, on the other hand, are migratory targets, while for Denmark, Germany, Italy, Israel, Norway, the Netherlands, Sweden, Switzerland and the UK we inferred significant bidirectional migration. For Poland no significant migratory pathways were inferred. Subtype B phylogeographies provide a new insight about the geographical distribution of viral lineages, as well as the significant pathways of virus dispersal across Europe, suggesting that intervention strategies should also address tourists, travellers and migrants.

3 April 2000 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PMP. Maggi
P. Maggi
ALA. M. V. Larocca
A. M. V. Larocca
MQM. Quarto
M. Quarto
GSGabriella Serio
Gabriella Serio
OBO. Brandonisio
O. Brandonisio
GPG. Pastore
G. Pastore